MedTrace Logo

Liquid Biopsy in Mature B-cell Tumors

NCT03280394 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 444

Last updated 2023-11-01

No results posted yet for this study

Summary

The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.

Conditions

  • Mature B-Cell Neoplasm

Interventions

DIAGNOSTIC_TEST

Liquid Biopsy

Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.

Sponsors & Collaborators

  • Oncology Institute of Southern Switzerland

    lead OTHER

Principal Investigators

  • Davide Rossi, MD, PhD · Oncology Institute of Southern Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280394 on ClinicalTrials.gov